Proactive Investors
26 Jan 2026, 15:40 UTC · 42w ago
Sarepta Therapeutics shares rise on positive Duchenne gene therapy data
Impact · against what's priced in
Sarepta Therapeutics receives a positive catalyst from three-year Phase 3 EMBARK data showing a statistically significant slowing of Duchenne muscular dystrophy progression. The quantifiable efficacy (70-73% reduction in progression) and lack of new safety signals provide strong fundamental support for long-term revenue growth.
- SRPT+0.70
No priced-in read yet
- In context
The three-year data showing a 73% reduction in disease progression (TTR) and 70% in 10MWR, combined with no new safety signals, provides concrete evidence of long-term efficacy that drives commercial valuation.
Read from the article alone





